Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2024; 13(03): 170-176
DOI: 10.1055/s-0043-1777727
Original Article
Breast Cancer

The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy—A Prospective Study

Rexeena V. Bhargavan
1   Department of Surgical Services, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Nisha Prasannan
2   Department of Surgical Oncology, KIMS Hospital, Thiruvananthapuram, Kerala, India
,
K.M. Jagathnath Krishna 
3   Department of Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Paul Augustine 
1   Department of Surgical Services, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Kurian Cherian
1   Department of Surgical Services, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Nisha Prasannan

Breast cancer is the most common female cancer in India, with a significant number presenting as locally advanced breast cancer (LABC). Level III clearance is routinely performed in our institute in LABC following neoadjuvant chemotherapy (NACT). In our previous retrospective study, level III positivity rate was 15.5%. We aim to prospectively assess level III positivity rate in LABC patients post-NACT. This is a prospective study of female patients with LABC (defined as cT3N1–3M0 or cT4N0–3M0 or cTanyN2,3M0) who received NACT and underwent surgery including level III dissection from November 2019 to October 2021. Data collected included age, menopausal status, TNM stage at presentation, grade, hormone receptor and HER2 status, treatment response, ycT and ycN stage, and final histopathology. Univariate and multivariate analysis was undertaken. p-Value less than or equal to 0.05 was considered significant. Study recruited 598 patients. Level III node positivity rate was 8.4%. The clinical complete response rate (cCR) was 36% (215/598). On univariate analysis, significant association was present between level III node and cCR (p < 0.01), ycT0 stage (p = 0.001), ycN0 stage (p = 0.028), level II node positivity (p = 0.001), ypT stage (p = 0.001), and ypN stage (p = 0.001). On multivariate analysis, significant association was present between level III node and ycT stage (p < 0.001), ypT stage (p = 0.001), and ypN stage (p = 0.001). Level III positivity rate in LABC post-NACT is high. In patients with advanced ycT stage, it would be advisable to offer complete axillary dissection including level III. Level III dissection may be avoided in patients with ycT0 or ycN0 or with cCR.

Keywords

level III dissection - locally advanced breast cancer - neoadjuvant chemotherapy - axillary dissection - level III positivity rate


Publication History

Article published online:
12 February 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6: 1063-1075
    CrossrefPubMedGoogle Scholar
  • 2 Dhanushkodi M, Sridevi V, Shanta V. et al. Locally advanced breast cancer (LABC): real-world outcome of patients from Cancer Institute, Chennai. JCO Glob Oncol 2021; 7: 767-781
    CrossrefPubMedGoogle Scholar
  • 3 Franceschini G, Martin Sanchez A, Di Leone A. et al. New trends in breast cancer surgery: a therapeutic approach increasingly efficacy and respectful of the patient. G Chir 2015; 36 (04) 145-152
    PubMedGoogle Scholar
  • 4 Pfob A, Heil J. Breast and axillary surgery after neoadjuvant systemic treatment - a review of clinical routine recommendations and the latest clinical research. Breast 2022; 62 (suppl 1, suppl 1): S7-S11
    CrossrefPubMedGoogle Scholar
  • 5 Krag DN, Anderson SJ, Julian TB. et al; National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8 (10) 881-888
    CrossrefPubMedGoogle Scholar
  • 6 Classe JM, Loaec C, Gimbergues P. et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 2019; 173 (02) 343-352
    CrossrefPubMedGoogle Scholar
  • 7 Kuehn T, Bauerfeind I, Fehm T. et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14 (07) 609-618
    CrossrefPubMedGoogle Scholar
  • 8 Boughey JC, Suman VJ, Mittendorf EA. et al; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310 (14) 1455-1461
    CrossrefPubMedGoogle Scholar
  • 9 Boileau JF, Poirier B, Basik M. et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015; Jan 20; 33 (03) 258-264
    CrossrefPubMedGoogle Scholar
  • 10 Caudle AS, Yang WT, Krishnamurthy S. et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016; 34 (10) 1072-1078
    CrossrefPubMedGoogle Scholar
  • 11 Donker M, Straver ME, Wesseling J. et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015; 261 (02) 378-382
    CrossrefPubMedGoogle Scholar
  • 12 Žatecký J, Kubala O, Coufal O. et al. Magnetic seed (Magseed) localisation in breast cancer surgery: a multicentre clinical trial. Breast Care (Basel) 2021; 16 (04) 383-388
    CrossrefPubMedGoogle Scholar
  • 13 Gasparri ML, de Boniface J, Poortmans P. et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg 2022; 109 (09) 857-863
    CrossrefPubMedGoogle Scholar
  • 14 Gradishar WJ, Anderson BO, Balassanian R. et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw 2017; 15 (04) 433-451
    CrossrefPubMedGoogle Scholar
  • 15 Joshi S, Noronha J, Hawaldar R. et al. Merits of level III axillary dissection in node-positive breast cancer: a prospective, single-institution study from India. J Glob Oncol 2019; 5: 1-8
    CrossrefPubMedGoogle Scholar
  • 16 Ortmann O, Blohmer JU, Sibert NT. et al; for 55 breast cancer centers certified by the German Cancer Society. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers. J Cancer Res Clin Oncol 2023; 149 (03) 1195-1209
    CrossrefPubMedGoogle Scholar
  • 17 Bhargavan RV, Mirza A, Cherian K, Krishna J, Augustine P. Level III dissection in locally advanced breast cancer following neoadjuvant chemotherapy: a retrospective study. Ann R Coll Surg Engl 2020; 102 (03) 214-219
    CrossrefPubMedGoogle Scholar
  • 18 Fan Z, Li J, Wang T. et al. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy. Breast 2013; 22 (06) 1161-1165
    CrossrefPubMedGoogle Scholar
  • 19 Hennessy BT, Hortobagyi GN, Rouzier R. et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23 (36) 9304-9311
    CrossrefPubMedGoogle Scholar
  • 20 Buzatto IP, Ribeiro-Silva A, Andrade JM, Carrara HH, Silveira WA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Braz J Med Biol Res 2017; 50 (02) e5674
    CrossrefPubMedGoogle Scholar
  • 21 Fisher B, Anderson S, Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16) 1233-1241
    CrossrefPubMedGoogle Scholar
  • 22 Hu J, Xia X, Yang H, Yu Y. Dissection of level III axillary lymph nodes in breast cancer. Cancer Manag Res 2021; 13: 2041-2046
    CrossrefPubMedGoogle Scholar
  • 23 Veronesi U, Cascinelli N, Mariani L. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347 (16) 1227-1232
    CrossrefPubMedGoogle Scholar
  • 24 Park S, Koo JS, Kim GM. et al. Feasibility of charcoal tattooing of cytology-proven metastatic axillary lymph node at diagnosis and sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients. Cancer Res Treat 2018; 50 (03) 801-812
    CrossrefPubMedGoogle Scholar
  • 25 Siso C, de Torres J, Esgueva-Colmenarejo A. et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol 2018; 25 (03) 784-791
    CrossrefPubMedGoogle Scholar
  • 26 Lowes S, Bell A, Milligan R, Amonkar S, Leaver A. Use of Hologic LOCalizer radiofrequency identification (RFID) tags to localise impalpable breast lesions and axillary nodes: experience of the first 150 cases in a UK breast unit. Clin Radiol 2020; 75 (12) 942-949
    CrossrefPubMedGoogle Scholar
  • 27 Laws A, Dillon K, Kelly BN. et al. Node-positive patients treated with neoadjuvant chemotherapy can be spared axillary lymph node dissection with wireless non-radioactive localizers. Ann Surg Oncol 2020; 27 (12) 4819-4827
    CrossrefPubMedGoogle Scholar
  • 28 Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML. EUBREAST Group. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 2021; 156 (06) e210891
    CrossrefPubMedGoogle Scholar
  • 29 von Minckwitz G, Huang CS, Mano MS. et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380 (07) 617-628
    CrossrefPubMedGoogle Scholar
  • 30 Masuda N, Lee SJ, Ohtani S. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376 (22) 2147-2159
    CrossrefPubMedGoogle Scholar
  • 31 Kong Y, Yang A, Xie X. et al. Impact of the extent of axillary surgery in patients with N2-3 disease in the de-escalation era: a propensity score-matched study. Clin Transl Oncol 2021; 23 (03) 526-535
    CrossrefPubMedGoogle Scholar